OncLive TV

Paolo Ghia, MD, PhD, discusses ongoing and future directions for the investigation of fixed-duration ibrutinib/venetoclax in CLL.

Yong Jae Lee, MD, PhD, discusses the clinical relevance of the preliminary safety of nivolumab for resectable mismatch repair–deficient endometrial cancer.

Paolo Tarantino, MD, discusses the evolving role of anthracycline- and taxane-based regimens in HER2-positive breast cancer.

Matthew Cortese, MD, MPH, discusses the methods used to produce a comprehensive map of immune changes that occur with venetoclax treatment in CLL.

Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.

Aiwu Ruth He, MD, PhD, discusses the significance of data from the CheckMate 9DW trial evaluating frontline nivolumab plus ipilimumab in metastatic HCC.

Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.

Nerea Lopetegui-Lia, MD, discusses treatment options for patients with chemotherapy-pretreated early-stage high-risk TNBC with residual disease at surgery.

Neeta Somaiah, MD, details challenges that are associated with pathology diagnosis, NGS, and early opinions for patients with sarcomas.

Claudia Aguilar Clancy, FNP-C, AOCNP, discusses the importance of individualized nutritional support as a component of oncology care.

Caroline Kozek, DNP, RN, AGNP-C, OCN, discusses a study assessing oncology nurses’ perceived difficulties in providing palliative care to adult patients.

Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.

David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Rachel N. Grisham, MD, discusses efficacy and tolerability data from the phase 2 ENGOT-OV60/GOG-3052/RAMP 201 subgroup analysis.

Bhagirathbhai Dholaria, MBBS, discusses the rationale and evolving investigation of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Mauricio Escobar, MD, discusses CDK4/6 inhibitor selection based on retrospective real-world analyses in HR-positive metastatic breast cancer.

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses CRs achieved with letrozole, abemaciclib, and metformin in ER–positive endometriod endometrial cancer.

Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.

Ecaterina Dumbrava, MD, discusses the rationale and clinical development of rezatapopt in ovarian cancer and other solid tumors harboring TP53 Y220C mutations.

Evan Ya-Wen Yu, MD, discusses considerations surrounding the tolerability of PARP inhibitors and how their adverse effect profiles influence treatment decisions in metastatic prostate cancer.

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.

Kelly E. McCann, MD, PhD, discusses the benefit of using TKI combinations for patients with HER2-positive breast cancer and brain metastases.